Larkberget ABOMXSTO: LARK

LARK: Gene therapy focus sharpened, COZY prioritized, and cost cuts extend liquidity to 2026

· Issued by Larkberget AB

Sharpened focus on gene therapy led to the termination of CG01 and CGT2, with all R&D now directed to the COZY program. Cost reductions extend liquidity to Q2 2026, while financials reflect lower revenue and continued operating losses.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

Larkberget AB on 6ix

Story so far

Earlier from Larkberget

Later from Larkberget

All Larkberget news releases